Home > Boards > Free Zone > Health and Sciences > Biotech Values

SNY -8% PM* on forecast of flat diabetes

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 739
Posts 113,349
Boards Moderated 15
Alias Born 09/05/02
160x600 placeholder
DewDiligence Member Level  Tuesday, 10/28/14 09:11:42 AM
Re: jq1234 post# 181659
Post # of 234208 
SNY -8% PM* on forecast of flat diabetes sales in 2015:

http://www.thestreet.com/story/12929731/1/sanofi-sny-stock-drops-today-as-diabetes-sales-expected-to-be-flat-in-2015.html
Quote:
Chief Executive Officer Chris Viehbacher said the drugmaker cut prices for its best-selling product, Lantus, last quarter to get on U.S. drug benefit managers' reimbursement lists in the face of competition from companies including Novo Nordisk…

Lantus has become the “next Advair” wrt pushback from payers.

*Trading lower in European home market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist